RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Vivoryon Therapeutics Stock

Vivoryon Therapeutics Equity 2024

Vivoryon Therapeutics Equity

26.28 M EUR

Ticker

VVY.AS

ISIN

NL00150002Q7

WKN

A2QJV6

In 2024, Vivoryon Therapeutics's equity was 26.28 M EUR, a -0.85% increase from the 26.51 M EUR equity in the previous year.

Vivoryon Therapeutics Aktienanalyse

What does Vivoryon Therapeutics do?

Vivoryon Therapeutics NV is a biopharmaceutical company specializing in the development of drugs for the treatment of Alzheimer's and other neurodegenerative diseases. The company was founded in 2016 in Leuven, Belgium and is headquartered in Heidelberg, Germany. Vivoryon Therapeutics has a history dating back to 2005 when it was supported by EFPIA-AIM. The company has since gone through several successful financing rounds to advance its research and development efforts. Its business model is based on the discovery and development of therapeutics with a new chemical approach to treating Alzheimer's and other neurodegenerative diseases. Vivoryon Therapeutics is currently involved in three different therapy areas: small molecule blockers, epigenetics, and big data analytics and telemetry technologies. The company is also developing a drug known as PQ912, which has the potential to slow down the progression of Alzheimer's disease. Vivoryon Therapeutics has partnerships and collaborations with various institutions to further its research and development programs. Overall, the company has the potential to revolutionize the treatment of Alzheimer's and other neurodegenerative diseases through its innovative efforts and collaborations. Vivoryon Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Vivoryon Therapeutics's Equity

Vivoryon Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Vivoryon Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Vivoryon Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Vivoryon Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Vivoryon Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Vivoryon Therapeutics stock

What is the equity of Vivoryon Therapeutics this year?

Vivoryon Therapeutics has equity of 26.28 M EUR this year.

What was the equity of Vivoryon Therapeutics compared to the previous year?

The equity of Vivoryon Therapeutics has increased/decreased by -0.85% decreased compared to the previous year.

What impact does a high equity have on investors of Vivoryon Therapeutics?

A high equity is advantageous for investors of Vivoryon Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Vivoryon Therapeutics?

A low equity can be a risk for investors of Vivoryon Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Vivoryon Therapeutics affect the company?

An increase in equity of Vivoryon Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Vivoryon Therapeutics affect the company?

A reduction in equity of Vivoryon Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Vivoryon Therapeutics?

Some factors that can affect the equity of Vivoryon Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Vivoryon Therapeutics so important for investors?

The equity of Vivoryon Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Vivoryon Therapeutics take to change the equity?

To change equity, Vivoryon Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Vivoryon Therapeutics pay?

Over the past 12 months, Vivoryon Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vivoryon Therapeutics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Vivoryon Therapeutics?

The current dividend yield of Vivoryon Therapeutics is .

When does Vivoryon Therapeutics pay dividends?

Vivoryon Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vivoryon Therapeutics?

Vivoryon Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Vivoryon Therapeutics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vivoryon Therapeutics located?

Vivoryon Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vivoryon Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vivoryon Therapeutics from 12/18/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 12/18/2024.

When did Vivoryon Therapeutics pay the last dividend?

The last dividend was paid out on 12/18/2024.

What was the dividend of Vivoryon Therapeutics in the year 2023?

In the year 2023, Vivoryon Therapeutics distributed 0 EUR as dividends.

In which currency does Vivoryon Therapeutics pay out the dividend?

The dividends of Vivoryon Therapeutics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Vivoryon Therapeutics

Our stock analysis for Vivoryon Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vivoryon Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.